Mode
Text Size
Log in / Sign up
N/A N=346

Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer

Breast Cancer · Colorectal Cancer · Kidney Cancer · Lung Cancer · Prostate Cancer

Enrolled (actual)
346
Serious AEs
Results posted
Jul 2025
Primary outcome: Primary: Priorities of Patients Receiving First Medical Treatment for Cancer at Treatment Initiation — 199; 93; 141; 80 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Consultation, evaluation questionnaire (Other); Geriatric consultation, evaluation questionnaire (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Institut Bergonié
Primary completion
Jun 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Priorities of Patients Receiving First Medical Treatment for Cancer at Treatment Initiation
199; 93; 141; 80; 181; 67
PRIMARY
Priorities of Patients Receiving First Medical Treatment for Cancer 3 Months After Initiation of Treatment
145; 85; 105; 72; 134; 66
SECONDARY
Expectations of Patients at Initiation of Treatment
3; 0; 4; 0; 5; 0
SECONDARY
Expectations of Patients 3 Months After Initiation of Treatment
1; 0; 5; 4; 9; 5
SECONDARY
Stability of Patients in Their Priorities at 3 Months
137; 82; 74; 62; 119; 51
SECONDARY
1-year Overall Survival
77.5; 85.2
SECONDARY
Agreement Rate for Prioritization of Expectations Between Patients and Physicians
174; 84; 123; 76; 128; 47

Summary

The main objective of study is to describe the priorities of elderly patients (70 years and over) undergoing a first medical treatment for cancer, at initiation of treatment and after 3 months of treatment. The main criterion is a prioritization of 4 items per patient from a list of 8 expectations regarding the objectives of their treatment: treatment efficacy, life expectancy, autonomy, daily activities, social activities, heaviness of treatment, toxicity, economics.

Eligibility Criteria

Inclusion Criteria

  • Male or female:
  • Age ≥ 70 years
  • Aged 18-69 years (case population)
  • ECOG / performance status 0-3 (WHO).
  • First line of medical oncology treatment (chemotherapy, targeted therapy, hormone therapy, combination):
  • Neo-adjuvant setting,
  • Adjuvant setting: previous neo-adjuvant treatment is allowed,
  • Metastatic setting: previous neo-adjuvant and/or adjuvant treatment are allowed,
  • Solid tumors (breast, colorectal, kidney, lung, prostate, sarcoma, and ovarian) and lymphoma (indolent and aggressive).
  • Life expectancy of more than 3 months.
  • Patients potentially compliant with the rules of the follow-up study.
  • Patients affiliated to a social security scheme.
  • Patients who received clear information from the investigator on the study and had not refused to participate.

Exclusion Criteria

  • Exclusive surgery treatment.
  • Exclusive radiotherapy treatment or in combination with oncological medical treatment (concomitant radio-chemotherapy or radio-hormonotherapy).
  • Previous first line of oncological medical treatment in the same indication as the one concerned by the inclusion:
  • Neo-adjuvant setting: previous line(s) of neo-adjuvant medical treatment,
  • Adjuvant setting: previous line(s) of adjuvant medical treatment,
  • Metastatic setting: previous line(s) of metastatic medical treatment,
  • Supportive care without specific medical treatment
  • Previous or ongoing cancer under treatment at the time of inclusion.
  • Patient already included in this study
  • Patient who for psychological, psychiatric, social, family or geographical reasons could not be regularly monitored according to the criteria of the study; patient private of liberty or under guardianship.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02821793). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search